Clinical study of valsartan combined with alprostadil in the treatment of patient with early diabetic nephropathy
10.13699/j.cnki.1001-6821.2016.05.008
- VernacularTitle:缬沙坦联合前列地尔对早期糖尿病肾病的临床研究
- Author:
Ya-Li MA
1
;
Fang CHEN
;
Jun SHI
;
Bao-Ping CHEN
Author Information
1. 河南大学 淮河医院 肾内科
- Keywords:
diabetic nephropathy;
valsartan;
alprostadil;
serumblood urea nitrogen ( BUN );
serum creatinine ( Scr );
urinary albumin excretion rate ( UAER)
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(5):409-411
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of al-sartan combined with alprostadil in the treatment of early diabetic ne-phropathy.Methods Ninety-eight early diabetic nephropathy patients were divided into three groups , 33 patients in group A , 31 patients in group B , and 34 patients in group C.Patients in group A were given al-prostadil 100 μg +0.9%NaCl 250 mL, qd.Patients in group B were given valsartan 80 mg, qd.And patients in group C were givenalprostadil 100 μg +0.9%NaCl 250 mL +valsartan 80 mg, qd.After 1 month treatment, the clinical efficacy and serum blood urea nitrogen ( BUN), serum creatinine(Scr) and urinary albumin excretion rate (UAER) were observed in two groups.Results Total efficacy were75.76%, 70.96%and 94.12% for group A, B and C, without no significant statistical difference( P >0.05 ).The BUN, Scr and UAER were significant de-creased after treatment for all three groups ( P<0.05 ) , group C much lower than other groups after treatment ( P<0.05 ).The incidence rates of adverse drug reactions were 9.09%, 12.90%and 11.76% for the 3 groups , with no statistical difference ( P>0.05 ).Conclusion The clini-cal efficacy of valsartan combined with alprostadil was superior to the sin-gle drug in the treatment of early diabetic nephropathy which could de-creased the BUN , Scr and UAER.
